Rhythm Pharmaceuticals (NASDAQ:RYTM) issued its quarterly earnings data on Sunday. The company reported ($1.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.30 by ($1.46), Fidelity Earnings reports.
Shares of RYTM stock traded down $0.42 during trading hours on Tuesday, reaching $21.53. The stock had a trading volume of 369,085 shares, compared to its average volume of 455,183. The stock’s fifty day simple moving average is $22.03 and its 200 day simple moving average is $26.59. The firm has a market capitalization of $1.08 billion, a PE ratio of -7.22 and a beta of 1.57. Rhythm Pharmaceuticals has a 12 month low of $17.27 and a 12 month high of $43.26.
In other news, CEO David P. Meeker purchased 10,000 shares of the business’s stock in a transaction on Tuesday, March 30th. The stock was purchased at an average cost of $20.17 per share, with a total value of $201,700.00. Following the acquisition, the chief executive officer now directly owns 111,335 shares in the company, valued at $2,245,626.95. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 9.49% of the company’s stock.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and AlstrÃ¶m syndrome.
Featured Story: Equity Income
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.